REG - Hemogenyx Pharma Plc - Admission of New Ordinary Shares and New ISIN

Hemogenyx PharmaceuticalsAnnouncement

10/12/2024 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241210:nRSJ5646Pa&default-theme=true

RNS Number : 5646P  Hemogenyx Pharmaceuticals PLC  10 December 2024

10 December 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Admission of New Ordinary Shares and New ISIN

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical company
developing innovative therapies for blood diseases, wishes to provide a
further update on the admission of the New Ordinary Shares (as defined below)
further to the passing of all resolutions at its Extraordinary General Meeting
(the "Meeting") held on 9 December 2024.

 

At the Meeting, resolutions were passed to approve the subdivision and
reclassification of the Company's existing 1,401,815,988 ordinary shares (the
"Existing Ordinary Shares") by 1:2 so that each Existing Ordinary Share was
subdivided and reclassified into 1 new ordinary share of £0.000025 each (the
"New Ordinary Shares") and 1 deferred share of £0.009975 each (the "Deferred
Shares"), followed by a consolidation of the New Ordinary Shares by 400:1 so
that every 400 New Ordinary Shares were consolidated into 1 New Ordinary Share
of £0.01 each (the "Capital Reorganisation"). As a result of the approval of
the Capital Reorganisation, the Company has 3,504,539 New Ordinary Shares in
issue.

 

Admission in respect of such New Ordinary Shares to the transition category of
the Official List of the FCA and to trading on the Main Market for listed
securities of the London Stock Exchange will become effective and dealings in
those New Ordinary Shares is expected on 13 December 2024. As a result of the
Capital Reorganisation, the ISIN of the New Ordinary Shares will change
from GB00BYX3WZ24 to GB00BQVXM815.

 

The Deferred Shares have no right to vote or participate in the capital of the
Company (save as set out in the Company's Articles of Association) and the
Company will not issue any certificates or credit CREST accounts in respect of
them. The Deferred Shares will not be admitted to trading on any exchange.

 

The rights of the New Ordinary Shares and the Deferred Shares are set out in
the new Articles of Association as adopted by the Company on 9th December
2024.

 

The above figure of 3,504,539 should be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune disease and to bring
the curative power of bone marrow transplantation to a greater number of
patients suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and complementary
product candidates, as well as a platform technology that it uses as an engine
for novel product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSQBLFFZLLBFBD